CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IMBiologics Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IMBiologics Corp
260 Changnyong-daero Yeongtong
Phone: +82 3180678172p:+82 3180678172 SUWON, 16229  South Korea Ticker: 493280493280
Business Summary
IMBiologics Corp is a Korea-based company primarily engaged in the research and development of novel antibody drugs. The Company's product portfolio includes IMB-101 and IMB-102. IMB-101 is an innovative biopharmaceutical designed to effectively suppress complex inflammatory pathways that are difficult to regulate with single-target therapies and is a dual antibody for the treatment of autoimmune diseases that simultaneously targets OX40 ligand (OX40L) and tumor necrosis factor (TNF). IMB-102 is a monoclonal antibody candidate for the treatment of autoimmune diseases designed to directly target OX40L, an upstream regulator of the immune response. The Company also provides related services.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202612/31/2025-----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Founder GyongsikHa
Chief Financial Officer, Chief of Management Support WanjunKim
Chief Operating Officer, Chief Business Officer, Head of Business Operation InsooJung
Chief Technology Officer, Head of R&D Center ChungminLee
Chief Development Officer, Head of Development dept. ChihyePark

General Information
Number of Employees: 46 (As of 3/31/2026)
Outstanding Shares: 14,827,449 (As of 5/29/2026)
Shareholders: 58
Stock Exchange: KDQ
Fax Number: +82 3180678169


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 1, 2026